Additionally, we observed that knocking down the CCTα, LPCAT3, or PEMT genes in HepG2 cells abolished ezetimibe’s ability to reduce oleate-induced triglyceride accumulation, suggesting the importance of these enzymes in mediating ezetimibe’s efficacy against NAFLD. The gene discussed is LPCAT3; the disease is metabolic dysfunction-associated steatotic liver disease.